...
首页> 外文期刊>Developmental and Comparative Immunology: Ontogeny, Phylogeny, Aging: The Official Journal of the International Society of Developmental and Comparative Immunology >Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases
【24h】

Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases

机译:在人类中广泛检测到对来自肿瘤相关抗原的CTL表位肽的体液免疫反应:恶性疾病患者总体生存的新生物标记

获取原文
获取原文并翻译 | 示例
           

摘要

Both cellular and humoral immune responses are crucial to induce potent anti-tumor immunity, but most of currently conducted peptide-based cancer vaccines paid attention to cellular responses alone, and none of them are yet approved as a therapeutic modality against cancer patients. We investigated humoral immune responses to CTL epitope peptides derived from tumor-associated antigens in healthy donors and patients with various diseases to facilitate better understanding of their distribution patterns and potential roles. Bead-based multiplex assay, ELISA, and Western blotting were used to measure immunoglobulins reactive to each of 31 different CTL epitope peptides. Importantly, the sums of anti-peptide IgG levels specific to 31 CTL epitope peptides were well correlated with better overall survival (OS) in patients with malignant diseases. Our results suggested that humoral immune responses to CTL epitope peptides were widely detectable in humans. Measurement of immunoglobulins specific to CTL epitope peptides may provide a new biomarker for OS of patients with malignant diseases, although it still remains to be determined whether the correlations between humoral immune responses to epitope peptides and OS are observed only for the CTL epitopes used, or also for other panels of peptides. Quantity of circulating IgG reactive to these peptides was also discussed.
机译:细胞和体液免疫应答对于诱导有效的抗肿瘤免疫都是至关重要的,但是大多数目前进行的基于肽的癌症疫苗只关注细胞应答,而且还没有一种被批准作为针对癌症患者的治疗方法。我们调查了健康供体和患有各种疾病的患者对源自肿瘤相关抗原的CTL表位肽的体液免疫反应,以促进对它们的分布方式和潜在作用的更好理解。基于微珠的多重测定,ELISA和Western blotting被用于测量对31种不同CTL表位肽中每一种都具有反应性的免疫球蛋白。重要的是,特异于31种CTL表位肽的抗肽IgG水平之和与恶性疾病患者更好的总体生存率(OS)密切相关。我们的结果表明,在人体中可广泛检测到对CTL表位肽的体液免疫反应。对CTL表位肽特异的免疫球蛋白的测量可能为恶性疾病患者的OS提供新的生物标志物,尽管仍然有待确定是否仅对所用的CTL表位观察到对表位肽的体液免疫应答与OS之间的相关性,还是尚待确定。也用于其他肽段。还讨论了对这些肽具有反应性的循环IgG的数量。

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号